HK Stock Market Move | SIHUAN PHARM (00460) surged over 4%. Its poly lactic acid facial filler "Youthful Injection" has been approved for market launch.

SIHUAN PHARM (00460) rose more than 4%, as of the time of writing, it is up 4.55% at 0.69 Hong Kong dollars, with a turnover of 26.8874 million Hong Kong dollars. On the news front, SIHUAN PHARM announced that its subsidiary Meiyana Biotechnology (Jilin) Co., Ltd. has independently developed a poly-lactic acid facial filler (the product) has officially obtained the third-class medical device registration certificate approved by the National Medical Products Administration, used to correct moderate to severe nasolabial folds. It is reported that the poly-lactic acid facial filler, market-named "youthful injection," with poly-L-lactic acid (PLLA) microspheres as its core component, has stable biological degradation characteristics, can stimulate the regeneration of autologous collagen protein, achieve "instant filling + long-lasting regeneration." The announcement stated that the approval of the group's independently developed "youthful injection" marks a double breakthrough for the group in the field of regenerative medical aesthetics: within just one month, the group's Meiyana Biotechnology has successively obtained the third-class medical device certification for two regenerative injection products, "youthful injection" and "youthful injection," becoming the only enterprise in China to hold both compliant "youthful injection" and "youthful injection" two major regenerative filling products, establishing a differentiated competitive advantage.